Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes.
Buprenorphine
Medication for opioid use disorder
Opioid use disorder
Psychosocial services
Therapy
Journal
Journal of substance abuse treatment
ISSN: 1873-6483
Titre abrégé: J Subst Abuse Treat
Pays: United States
ID NLM: 8500909
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
29
10
2021
revised:
02
02
2022
accepted:
15
03
2022
pubmed:
27
3
2022
medline:
14
6
2022
entrez:
26
3
2022
Statut:
ppublish
Résumé
Current evidence indicates that buprenorphine is a highly effective treatment for opioid use disorder (OUD), though premature medication discontinuation is common. Research on concurrent psychosocial and behavioral therapy services and related outcomes is limited. The goal of this study was to define patterns of OUD-related psychosocial and behavioral therapy services received in the first 6 months after buprenorphine initiation, identify patients' characteristics associated with service patterns, and examine the course of buprenorphine treatment, including the association of therapy with medication treatment duration. We analyzed 2013-2018 MarketScan Multi-State Medicaid claims data. The sample included adults aged 18-64 years at buprenorphine initiation with treatment episodes of at least 7 days (n = 61,976). We used group-based trajectory models to define therapy service patterns and multinomial logistic regression to identify pre-treatment patient characteristics associated with therapy trajectories. Multinomial propensity-score weighted Cox proportional hazards regression estimated time to buprenorphine discontinuation and unweighted Cox proportional hazards models estimated risk of adverse health care events during buprenorphine treatment (all-cause and opioid-related inpatient and emergency department services, overdose treatment). We identified three trajectories of psychosocial and behavioral therapy services: none (73.8%), low-intensity (17.2%), and high-intensity (9.0%). Compared to those without therapy, low-intensity and high-intensity service patterns were associated with behavioral health diagnoses and medical treatment for opioid overdose in the baseline period prior to buprenorphine initiation. The hazard of buprenorphine discontinuation was significantly lower for low-intensity (HR = 0.55; 95% CI, 0.54-0.57) and high-intensity (HR = 0.71; 95% CI, 0.67-0.74) therapy groups compared to those without therapy services. Yet patients in the high-intensity therapy group had increased risk of opioid-related health care events during buprenorphine treatment, including medical treatment for opioid overdose (HR = 1.29; 95% CI, 1.01-1.64). Most patients received little or no OUD-related psychosocial and behavioral therapy after initiating buprenorphine treatment. Patients who received therapy had characteristics indicating greater treatment needs as well as more complex treatment courses. Concurrent therapy services may help to address premature buprenorphine discontinuation, particularly for patients with high-risk clinical profiles; however, future prospective research should determine whether therapy is effective for extending buprenorphine retention.
Identifiants
pubmed: 35337716
pii: S0740-5472(22)00056-3
doi: 10.1016/j.jsat.2022.108774
pmc: PMC9187597
mid: NIHMS1793533
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
108774Subventions
Organisme : NIDA NIH HHS
ID : K01 DA049950
Pays : United States
Organisme : NIDA NIH HHS
ID : K23 DA044342
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR003017
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Références
Lancet. 2019 Apr 27;393(10182):1760-1772
pubmed: 30878228
J Addict Dis. 2016;35(1):22-35
pubmed: 26467975
Health Aff (Millwood). 2020 May;39(5):747-755
pubmed: 32364847
J Subst Abuse Treat. 2020 Aug;115:108040
pubmed: 32600627
JAMA Pediatr. 2018 Nov 1;172(11):1029-1037
pubmed: 30208470
Subst Abuse Rehabil. 2018 Sep 21;9:59-78
pubmed: 30310349
J Subst Abuse Treat. 2021 Jan;120:108163
pubmed: 33298301
JAMA. 2020 Dec 15;324(23):2440-2442
pubmed: 33320214
Drug Alcohol Depend. 2021 Nov 1;228:108923
pubmed: 34508958
J Subst Abuse Treat. 2018 Dec;95:9-17
pubmed: 30352671
J Subst Abuse Treat. 2013 May-Jun;44(5):481-7
pubmed: 23265445
Health Aff (Millwood). 2016 Dec 1;35(12):2289-2296
pubmed: 27920318
Cochrane Database Syst Rev. 2011 Oct 05;(10):CD004147
pubmed: 21975742
Drug Alcohol Depend. 2011 Aug 1;117(1):24-30
pubmed: 21277704
Annu Rev Clin Psychol. 2010;6:109-38
pubmed: 20192788
Stat Med. 2013 Aug 30;32(19):3388-414
pubmed: 23508673
Drug Alcohol Depend. 2014 May 1;138:240-3
pubmed: 24656054
Addiction. 2014 Jan;109(1):79-87
pubmed: 23961726
Am J Epidemiol. 2011 Apr 1;173(7):761-7
pubmed: 21385832
Drug Alcohol Depend. 2019 Apr 1;197:78-82
pubmed: 30784952
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
J Addict Med. 2020 Mar/Apr;14(2S Suppl 1):1-91
pubmed: 32511106
Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207
pubmed: 24500948
J Subst Abuse Treat. 2018 Aug;91:57-68
pubmed: 29910015
J Addict Med. 2015 Nov-Dec;9(6):470-7
pubmed: 26517324
Arch Gen Psychiatry. 2011 Apr;68(4):419-27
pubmed: 21464366
J Addict Med. 2016 Mar-Apr;10(2):93-103
pubmed: 26808307
Med Care. 2017 Jul;55(7):698-705
pubmed: 28498196
J Subst Abuse Treat. 2019 Sep;104:135-143
pubmed: 31370977